TY - THES A1 - Torzewska, Agata T1 - Method development for quantification of prescription drugs Fluphenazine and Flupentixol in serum. N2 - The LVR clinic in Viersen belongs to a group of nine psychiatric clinics in NRW, Germany. In the pharmacy laboratory, the therapeutic drug monitoring is offered for antiepileptic drugs (AED´s), neuroleptics and antidepressants. Fluphenazine and Flupentixol are used to relieve the symptoms of schizophrenia and other similar mental health problems. The purpose of this work is the development and validation of methods for quantitation of the neuroleptics Fluphenazine and Flupentixol, contained in human serum. Therapeutic drug monitoring (TDM) is very important for a patient-matched therapy. TDM is applied to handle and direct the pharmacotherapy because of the pharmacokinetic differences between different individuals. The developed methods should be afterwards introduced into the daily routine of the laboratory. The analytical device used for this purpose is a Liquid Chromatography with a Mass Spectrometer (LCMS), with a Biphenyl Accucore separation column which is also used for other neuroleptics quantised. For Fluphenazine, an already existing in the laboratory sample precipitation method was used. Also, an already applied for other similar neuroleptics LCMS method, called “Biphenyl03_new” (lasting for 11 minutes, with a high gradient between the elution agents) was taken on, and resulted in a good linearity. In case of Flupentixol, a completely new method had to be established, in order to achieve a baseline separation of cis-Z-Flupentixol and trans-E-Flupentixol. For the sample preparation, a solid phase extraction method was developed. The established methods were then applied for quantitation of patient samples, and the stability of the measurements was proved. Also, the accuracy and precision of obtained results was tested in the Proficiency Test. Limit of quantitation achieved for Fluphenazine was 0,5ng/ml, whereas for Flupentixol the LOQ was 0,25ng/ml. The Limit of detection found was 0,05ng/ml for both substances. The development was successful for both analytes and the established methods were integrated into the daily routine of the laboratory. Y1 - 2022 UR - https://opus4.kobv.de/opus4-rhein-waal/frontdoor/index/index/docId/1271 UR - https://nbn-resolving.org/urn:nbn:de:hbz:1383-opus4-12715 ER -